Adenoviral-mediated Rybp expression promotes tumor cell-specific apoptosis

Cancer Gene Therapy

Volumn 15, Issue 11, 2008, Pages 713-722

  Novak, R L ^a   Phillips, A C ^a,b  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b ABBOTT LABORATORIES   (United States)

Author keywords

Adenovirus; Rybp; Tumor specific killing

Indexed keywords

ADENOVIRUS VECTOR; DEATH RECEPTOR; ETOPOSIDE; PROTEIN; PROTEIN RYBP; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER GENE THERAPY; CELL GROWTH; CELL LINE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; GENE THERAPY; GROWTH INHIBITION; HUMAN; HUMAN CELL; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL;

ADENOVIRIDAE; APOPTOSIS; CASPASES; CELL LINE, TUMOR; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; IMMUNOBLOTTING; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; OSTEOSARCOMA; TUMOR NECROSIS FACTOR-ALPHA;

ADENOVIRIDAE;

EID: 53549111610     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2008.25     Document Type: Article

References (29)

1. McCormick F. Cancer gene therapy: fringe or cutting edge? Nat Rev Cancer 2001; 1: 130-141.
2. Maddika S, Mendoza FJ, Hauff K, Zamzow CR, Paranjothy T, Los M. Cancer-selective therapy of the future: apoptin and its mechanism of action. Cancer Biol Ther 2006; 5: 10-19.
3. Maddika S, Booy EP, Johar D, Gibson SB, Ghavami S, Los M. Cancer-specific toxicity of apoptin is independent of death receptors but involves the loss of mitochondrial membrane potential and the release of mitochondrial cell-death mediators by a Nur77-dependent pathway. J Cell Sci 2005; 118(Part 19): 4485-4493.
4. Danen-van Oorschot AA, Voskamp P, Seelen MC, van Miltenburg MH, Bolk MW, Tait SW et al. Human death effector domain-associated factor interacts with the viral apoptosis agonist Apoptin and exerts tumor-preferential cell killing. Cell Death Differ 2004; 11: 564-573.
5. Bejarano F, Gonzalez I, Vidal M, Busturia A. The Drosophila RYBP gene functions as a Polycomb-dependent transcriptional repressor. Mech Dev 2005; 122: 1118-1129.
6. Garcia E, Marcos-GutierrezC, del Mar Lorente M, Moreno JC, Vidal M. RYBP, a new repressor protein that interacts with components of the mammalian Polycomb complex, and with the transcription factor YY1. EMBO J 1999; 18: 3404-3418.
7. Schuettengruber B, Chourrout D, Vervoort M, Leblanc B, Cavalli G. Genome regulation by polycomb and trithorax proteins. Cell 2007; 128: 735-745.
8. Schlisio S, Halperin T, Vidal M, Nevins JR. Interaction of YY1 with E2Fs, mediated by RYBP, provides a mechanism for specificity of E2F function. EMBO J 2002; 21: 5775-5786.
9. Sawa C, Yoshikawa T, Matsuda-Suzuki F, Deléhouzée S, Goto M, Watanabe H et al. YEAF1/RYBP and YAF-2 are functionally distinct members of a cofactor family for the YY1 and E4TF1/hGABP transcription factors. J Biol Chem 2002; 277: 22484-22490.
10. Trimarchi JM, Fairchild B, Wen J, Lees JA. The E2F6 transcription factor is a component of the mammalian Bmi1-containing polycomb complex. Proc Natl Acad Sci USA 2001; 98: 1519-1524.
11. Pirity MK, Locker J, Schreiber-Agus N. Rybp/DEDAF is required for early postimplantation and for central nervous system development. Mol Cell Biol 2005; 25: 7193-7202.
12. Pirity MK, Wang WL, Wolf LV, Tamm ER, Schreiber-Agus N, Cvekl A. Rybp, a polycomb complex-associated protein, is required for mouse eye development. BMC Dev Biol 2007; 7: 39.
13. Zheng L, Schickling O, Peter ME, Lenardo MJ. The death effector domain-associated factor plays distinct regulatory roles in the nucleus and cytoplasm. J Biol Chem 2001; 276: 31945-31952.
14. Barnhart BC, Lee JC, Alappat EC, Peter ME. The death effector domain protein family. Oncogene 2003; 22: 8634-8644.
15. Schickling O, Stegh AH, Byrd J, Peter ME. Nuclear localization of DEDD leads to caspase-6 activation through its death effector domain and inhibition of RNA polymerase I dependent transcription. Cell Death Differ 2001; 8: 1157-1168.
16. Verma IM, Weitzman MD. Gene therapy: twenty-first century medicine. Annu Rev Biochem 2005; 74: 711-738.
17. Yang ZR, Wang HF, Zhao J, Peng YY, Wang J, Guinn BA et al. Recent developments in the use of adenoviruses and immunotoxins in cancer gene therapy. Cancer Gene Ther 2007; 14: 599-615.
18. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 1998; 95: 2509-2514.
19. Xia Y, Novak R, Lewis J, Duckett CS, Phillips AC. Xaf1 can cooperate with TNFalpha in the induction of apoptosis, independently of interaction with XIAP. Mol Cell Biochem 2006; 286: 67-76.
20. Fang B, Roth JA. The role of gene therapy in combined modality treatment strategies for cancer. Curr Opin Mol Ther 2003; 5: 475-482.
21. Wakelee H, Belani CP. Optimizing first-line treatment options for patients with advanced NSCLC. Oncologist 2005; 10(Suppl 3): 1-10.
22. Longhi A, Errani C, De Paolis M, Mercuri M, Bacci G. Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat Rev 2006; 32: 423-436.
23. Dempsey PW, Doyle SE, He JQ, Cheng G. The signaling adaptors and pathways activated by TNF superfamily. Cytokine Growth Factor Rev 2003; 14: 193-209.
24. Fridman JS, Lowe SW. Control of apoptosis by p53. Oncogene 2003; 22: 9030-9040.
25. Fulda S, Debatin KM. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 2006; 25: 4798-4811.
26. Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 2005; 4: 307-320.
27. Montecucco A, Biamonti G. Cellular response to etoposide treatment. Cancer Lett 2007; 252: 9-18.
28. Creaven PJ, Plager JE, Dupere S, Huben RP, Takita H, Mittelman A et al. Phase I clinical trial of recombinant human tumor necrosis factor. Cancer Chemother Pharmacol 1987; 20: 137-144.
29. Held J, Schulze-Osthoff K. Potential and caveats of TRAIL in cancer therapy. Drug Resist Updat 2001; 4: 243-252.